Carfilzomib, Lenalidomide, and Dexamethasone Before and After Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma

Newly diagnosed, myeloma requiring systemic chemotherapy as per International Myeloma Working Group (IMWG) uniform criteria:

* Prior treatment of hypercalcemia or spinal cord compression or active and/or aggressively progressing myeloma with corticosteroids or lenalidomide or bortezomib-based regimens does not disqualify the patient (the treatment dose should not exceed the equivalent of 160 mg of dexamethasone in a 4 week period or not more than 1 cycle)

* Bisphosphonates are permitted

Suitable and interested to proceed to ASCT

Measurable disease, prior to initial treatment as indicated by one or more of the following:

* Serum monoclonal (M)-protein \>= 0.5 g/dL

* Urine M-protein \>= 200 mg/24 hours

* If serum protein electrophoresis is felt to be unreliable for routine M-protein measurement, then quantitative immunoglobulin levels are acceptable

Life expectancy of more than 3 months

Eastern Cooperative Oncology Group (ECOG) performance status 0-2

Bilirubin \< 1.5 times the upper limit of normal (ULN)

Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) \< 2.5 times ULN

Absolute neutrophil count (ANC) \>= 1.0 x 10\^9/L

Hemoglobin \>= 8 g/dL

Platelet count \>= 75 x 10\^9/L; subjects may receive red blood cell (RBC) transfusions or platelet transfusions, if clinically indicated in accordance with institutional guidelines; however, screening platelet count should be independent of platelet transfusions for at least 2 weeks

Calculated or measured creatinine clearance of \>= 50 mL/minute, calculated using the formula of Cockcroft and Gault

Written informed consent in accordance with federal, local, and institutional guidelines

Females of childbearing potential (FCBP) (defined as sexually mature females who: have not undergone a hysterectomy or bilateral oophorectomy; or have not been naturally postmenopausal for at least 24 consecutive months \[ie, has had menses at any time in the preceding 24 consecutive months\]) must agree to ongoing pregnancy testing

FCBP must have 2 negative pregnancy tests (sensitivity of at least 50 mIU/mL) prior to initiating lenalidomide; the first pregnancy test must be performed within 10-14 days before day 1 cycle 1 and the second pregnancy test must be performed within 24 hours of day 1 cycle 1; the subject may not receive lenalidomide until the treating investigator has verified that the results of these pregnancy tests are negative, and must agree to ongoing pregnancy tests as outlined in the protocol

FCBP must agree to use 2 reliable forms of contraception simultaneously or to practice complete abstinence from heterosexual intercourse during the following time periods related to this study:

* For at least 28 days before starting lenalidomide

* While participating in the study; and

* For at least 28 days after discontinuation from the study; the 2 methods of reliable contraception must include a highly effective method (ie, intrauterine device (IUD), hormonal \[birth control pills, injections, or implants\], tubal ligation, partner's vasectomy) and an additional effective (barrier) method (ie, latex condom, diaphragm, cervical cap); FCBP must be referred to a qualified provider of contraceptive methods if needed

Male subjects must agree to use a latex condom during sexual contact with females of childbearing potential while participating in the study and for at least 28 days following discontinuation from the study even if he has undergone a successful vasectomy

Male subjects must agree to inform his physician if he has had unprotected sexual contact with a female who can become pregnant or if he thinks for any reason that his sexual partner may be pregnant

Male subjects must agree not to donate semen or sperm while taking lenalidomide

All study participants must be registered into the mandatory Rev Assist program and be willing and able to comply with the requirements of Rev Assist

The ability to take aspirin or other appropriate venous thromboembolism (VTE) prophylaxis

Subjects must agree to adhere to all study requirements, including birth control measures and pregnancy testing, visit schedule, outpatient treatment, required concomitant medications, and laboratory monitoring

What this study is about